TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Mean difference in body fat mass percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: amount of food eaten
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subjective preprandial hunger feelings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of IOP-lowering medications at day 21
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased ocular hyperemia
Endpoint domain: Adverse events/effects
Primary endpoint: confirmed point prevalence abstinence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 50% or greater smoking reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean reduction of cigarettes per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6MWD (six-minute walk distance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PAP (pulmonary artery pressure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 10-year survival probability
Endpoint domain: Mortality/survival
Primary endpoint: relapse free survival probability
Endpoint domain: Mortality/survival
Primary endpoint: Mean increase on Hamilton Depression Rating Scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fulfillment of relapse criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gallbladder volume increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ursodeoxycholic acid serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Individual success rates in endotracheal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urinary function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: erection function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: ejaculation function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: number of resorption craters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average volume of resorption craters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of PF‐045237655
Endpoint domain: Adverse events/effects
Primary endpoint: absence of disease or very mild disease at week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patients rating their scalp psoriasis as clear or almost clear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of lesional/perilesional adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Serum cefazolin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tissue cefazolin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cardiovascular or thromboembolic toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical response measured by SCL-anxiety subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Side effects experienced at different doses of citalopram
Endpoint domain: Adverse events/effects
Primary endpoint: clinically relevant memory improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood-oxygen level dependent activity levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: EQ VAS score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Average satisfaction scores for HERMES operations
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Oral diabetes medication adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lipid-lowering medication adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: yearly lesion growth rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: incidence of choroidal neovascularization
Endpoint domain: Adverse events/effects
Primary endpoint: Mean increase of ejection fraction (EF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of LDL cholesterol plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: frequency rate of hyperglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: numbers and types of infections
Endpoint domain: Adverse events/effects
Primary endpoint: Scored intubation points
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bioavailability of oral cyclosporine preparations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: new rejection episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Range of Motion (ROM) gains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: percent of symptom-free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: wheezing score at 7th day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of inhaled ß2 ‐agonist rescue episodes per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum oleic acid (OA) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: MUFAs concentration in serum phospholipid fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Markers of glycemic control (HbA1c and fasting blood glucose)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean SCORAD index improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: KAP
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Reduction of symptomatic drug consumption
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement on painful symptomatology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Improvement on functional capacities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: cardiac hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: total hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Mean stool volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge of universal precautions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance with universal precautions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SF36
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Ankle Hindfoot Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Choline levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: BMI-for-age z-score (BMIZ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rapid weight gain from baseline to follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-responsive feeding practices
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Incidence of symptomatic intracranial hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: Mean 24-hour intragastric pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentages of time intragastric pH was above 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentages of time intragastric pH was above 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Quality-adjusted life-year (QALY) gain
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Clinical improvement of nocturnal sialorrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conjugated bilirubin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Total bile acids levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Median clinical improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Good or excellent clearance rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Patient preference for continued treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Occurrence of gastroduodenal ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Development of gastroduodenal erosions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Dyspepsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: One-year Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of days completed ≥4 SMBG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported severity of stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myotonia duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS score of pain reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total curative effective rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: VO2 cost during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: VE cost during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Child's behaviour response to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean eGFR slope
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: incidence of gouty arthritis
Endpoint domain: Adverse events/effects
Primary endpoint: Mean loss of body mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: discussions of family cancer history
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: discussions of personal breast cancer risk
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: discussions of genetic counseling/testing
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: fraction of alveolar granulocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: alveolar TNFalpha levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Intraoperative oculocardiac reflex incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Time of discharge from the hospital
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of CMV-infection and disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time to become pain-free
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived warmth at the feet
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Positive and Negative Syndrome Scale total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early treatment discontinuation rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Average number of bubbles in the pulmonary artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vascular hypertrophy in small arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Risk of postoperative pulmonary complications (PPCs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sedation satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: sensitivity and specificity values for detection of acute appendicitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Community-based service attendance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Validated quit rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: actuarial rate of treatment failure
Endpoint domain: Mortality/survival
Primary endpoint: access to care
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Frequency of physician response
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Risk of diabetes mellitus outside of pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in BAI scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: STAT5 phosphorylation in skeletal muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Prevalence of pressure sores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Prevalence of urinary tract infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of re-admissions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: risk for hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: risk for emergency department event
Endpoint domain: Mortality/survival
Primary endpoint: annual asthma care costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Spherical Equivalent (SE) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Axial Length (AL) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chest press improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle mass change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum concentrations of ammonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum concentrations of glutamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: systemic urea levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pain at 6 weeks postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rosuvastatin area under the plasma concentration‐time curve (AUC(0‐t))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum observed rosuvastatin plasma concentration (C(max))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in drug costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Levels of malondialdehyde (MDA) and superoxide dismutase (SOD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postoperative discharge time
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: delivery rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Percentage of patients with <200 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flatulence severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Quality of life estimated by BAROS
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: mucosal inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: comfort scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median sST2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left Ventricular ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Stop Signal Reaction Time (SSRT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of women reporting no urinary incontinence episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: RGV after ingestion of CHO beverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: colorectal cancer-related mood disturbances
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: situational anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: risk reduction effects of BIs for cannabis use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decision making
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Decision self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incremental Cost-Effectiveness Ratio (ICER) per Quality-Adjusted Life-Year (QALY)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reliability of remote motor scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Meal-stimulated CCK levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Meal-stimulated PP secretions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Glucose homeostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Infant outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Intimate partner violence
Endpoint domain: Adverse events/effects
Primary endpoint: Cut capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Adherence of fragments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Coagulation capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reduction in large local reactions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of pruritus, urticaria, and angioedema symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prevalence of cervical chlamydial trachomatis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Sensitivity of the scoring system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of the scoring system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of myoclonic seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Frequency of tonic-clonic seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: severe dyspnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of serious coughing
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of agitation
Endpoint domain: Adverse events/effects
Primary endpoint: Development of post-antibiotic vulvovaginitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Plasma bilirubin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Legibility of prescriptions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of signed prescriptions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Documentation of doses and routes of administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adenosine monophosphate (AMP) threshold concentration improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mannitol threshold dose improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Recovery time reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: No recurrences of skin lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative analgesia effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total morphine consumption during the first 24h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PVR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WHO FC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OLP at intracuff pressure of 60 cm H2 O
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: endoscopically confirmed healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes